SureTrader
Home > Boards > US Listed > Biotechs > Advaxis, Inc. (ADXS)

AT-014 Approval Path...

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
gbrown6332 Member Profile
 
Followed By 1
Posts 193
Boards Moderated 0
Alias Born 11/24/15
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 2/22/2018 5:36:43 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/22/2018 5:36:16 PM
Advaxis Prices $20.0 Million Public Offering of Common Stock Business Wire - 2/22/2018 9:15:00 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/21/2018 4:20:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/21/2018 4:17:01 PM
Advaxis Announces Proposed Public Offering of Common Stock Business Wire - 2/21/2018 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/15/2018 5:29:09 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/13/2018 5:33:13 PM
Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of M... Business Wire - 2/13/2018 8:30:00 AM
Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic ... Business Wire - 2/12/2018 9:15:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/6/2018 5:02:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/2/2018 4:37:57 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/29/2018 5:04:42 PM
Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conferen... Business Wire - 1/29/2018 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 1/25/2018 5:04:55 PM
Traders News Source Issues Stocks on Watch and a New Feature Report InvestorsHub NewsWire - 1/25/2018 8:05:00 AM
Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in Internation... Business Wire - 1/25/2018 8:00:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 1/9/2018 5:18:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:02:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/3/2018 6:01:39 PM
Annual Report (10-k) Edgar (US Regulatory) - 12/21/2017 6:05:52 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/20/2017 4:21:23 PM
Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update Business Wire - 12/20/2017 4:15:00 PM
gbrown6332   Friday, 10/06/17 11:53:35 AM
Re: None
Post # of 56705 
AT-014 Approval Path...

Just finished a fairly deep dive into USDA animal drug approval references. It's a bit puzzling as the references invariably lead back to FDA offices that appear to be the final word on veterinary drug oversight and approval.

This link provides what I believe is the actual path AT-014 must travel to conditional approval. A 9 page overview that defines the various authorities within the FDA who touch or manage the review and approval of new animal drugs.

Central to the process is the FDA Office of New Animal Drug Evaluation - ONADE. It's clear the drug sponsor, PETX in this case, has a key role in pushing the approval process via essential data the FDA ONADE requires to greenlight a new drug for marketing and use.

https://www.fsis.usda.gov/wps/wcm/connect/3667ee98-1f1b-4f79-8094-8bfbcc6c89fe/FDA_Animal_Drug_Approval.pdf?MOD=AJPERES

I searched in vain on the USDA and FDA animal drug databases to find any mention of pending actions for Aratana, PETX or AT-014. Doesn't mean the information isn't there, just may suggest I'm a lousy researcher. The Greenbook PDF of FDA approved animal drugs contains hundreds of references with a small handful of companies clearly dominating the new drug submission process. Our partner, Aratana, had three drugs listed.

Still hoping PETX surprises and hits their stated end of year approval target.

G.B.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist